Utilization of Quantitative EEG Spectral Analysis to Characterize IV Ganaxolone PK/PD Properties in Refractory Status Epilepticus (RSE) (Epilog) Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder with Comorbid Lennox-Gastaut Syndrome: A Post-hoc Analysis from the Marigold Study CT)Įxtended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up CT)Īggregated Safety and Tolerability Experience from the Ganaxolone Development Programĭate/Time: Sunday Dec. Longitudinal Relationship Between Seizure Burden and Developmental Progression and the Implications on Quality of Life in Children with CDKL5 Deficiency Disorderĭate/Time: Saturday Dec.
The Annual Meeting is also available virtually through AES 2021 Digital Select. “In addition, we’re pleased to share new data from the growing body of evidence supporting the use of IV ganaxolone in the acute care setting, with a quantitative EEG analysis and case studies of patients in super-refractory status epilepticus that further demonstrate the potential of ganaxolone in treating seizure disorders.”ĪES is the premier event for epilepsy professionals in academia, clinical practice, industry and patient advocacy. “Alongside new quality of life and extended safety and efficacy data of ganaxolone in CDKL5 deficiency disorder-our lead indication currently under FDA review-we look forward to highlighting data in tuberous sclerosis complex and Lennox-Gastaut syndrome that we believe support our clinical development plans in both indications,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals.
#Seizure activity on eeg trial
(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that nine abstracts highlighting clinical trial and research data have been accepted for poster presentation at the American Epilepsy Society (AES) Annual Meeting being held in Chicago, Illinois, from December 3 through 7, 2021. RADNOR, Pa.-( BUSINESS WIRE)- Marinus Pharmaceuticals, Inc.
0 kommentar(er)
